Middle East and Africa Ocular Drug Delivery Market Outlook and Strategic Insights by 2028

The ocular drug delivery market in Middle East & Africa is expected to grow to US$ 830.88 million by 2028 from US$ 1,272.46 million in 2021. The market is estimated to grow at a CAGR of 6.3% from 2021 to 2028.

Several players operating in the ocular drug delivery market are developing and launching innovative products. The strategy of development and launch of new products helps companies to cater to a broad customer base. For instance, in June 2020, Senju Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced the launch of a new combination ophthalmic solution, AILAMIDE Combination Ophthalmic Suspension, for the treatment of glaucoma and ocular hypertension. Additionally, in May 2019, Menicon Co., Ltd launched Menicon Bloom Myopia Control Management System. Menicon Bloom Night therapy includes the overnight wearing of a specifically designed reverse geometry orthokeratology contact lens—manufactured in hyper oxygen-permeable Menicon Z rigid material that guarantees ideal corneal oxygenation for comfortable contact lens wear. Such developments and launches of new products are emerging as a key trend in the ocular drug delivery market.

The COVID-19 pandemic has become the most significant challenge in the region. Middle East countries have been registered a growth in the number of COVID cases. Many countries in the region have less developed and underfunded health systems. Apart from this, a huge population already face a growing burden of non-communicable diseases, making them more vulnerable to the virus. However, in view of the 'social distancing' requirements, many conferences across the globe have been cancelled or postponed. One of the largest ophthalmic conferences, the World Ophthalmic Congress, which was supposed to be held in Cape Town, South Africa has gone completely online with a virtual conference. These factors are expected to negatively impact the growth of the ocular drug delivery market in the region for short terms. However, as the vaccination progresses, and pandemic situation is under control the region will offer several growth prospects for the market player in ocular drug delivery market.

With the new features and technologies, companies can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the ocular drug delivery market. The Middle East & Africa ocular drug delivery market is expected to grow at a good CAGR during the forecast period.

Middle East & Africa Ocular Drug Delivery Market Segmentation

Middle East & Africa Ocular Drug Delivery Market – By Technology

• Implantable Ocular Drug Delivery Systems
• Particulate Drug Delivery Systems
• Nano-Particle Drug Delivery System
• Others

Middle East & Africa Ocular Drug Delivery Market – By Formulation Type

• Solution
• Ointment
• Suspension
• Emulsion
• Liposomes and Nanoparticles

Middle East & Africa Ocular Drug Delivery Market – By Disease type

• Cataract
• Dry Eye Syndrome
• Macular Degeneration
• Glaucoma
• Diabetic Retinopathy
• Diabetic Macular Edema
• Others

Middle East & Africa Ocular Drug Delivery Market – By End User

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers

Middle East & Africa Ocular Drug Delivery Market – By Country

• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• Canada
• Mexico

Middle East & Africa Ocular Drug Delivery Market – Companies Mentioned

• AbbVie Inc.                                              
• Bausch Health Companies Inc.            
• Novartis AG                                            
• Clearside Biomedical, Inc                                       
• Alimera Sciences, Inc.              

Middle East and Africa Ocular Drug Delivery Report Scope